Evidence map›Paper›PMID 26021842›Full record

ArticlePituitary2015

Prevalence of AIP mutations in a series of Turkish acromegalic patients: are synonymous AIP mutations relevant?

Z Karaca, S Taheri, F Tanriverdi, K Unluhizarci, F Kelestimur

Abstract read
PubMed Publisher
In one paragraph

Article in Pituitary, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Z KaracaDepartment of Endocrinology, Erciyes University Medical School, 38039, Kayseri, Turkey.
S TaheriDepartment of Medical Biology, Erciyes University Medical School, Kayseri, Turkey.
F TanriverdiDepartment of Endocrinology, Erciyes University Medical School, 38039, Kayseri, Turkey.
K UnluhizarciDepartment of Endocrinology, Erciyes University Medical School, 38039, Kayseri, Turkey.
F KelestimurDepartment of Endocrinology, Erciyes University Medical School, 38039, Kayseri, Turkey. fktimur@erciyes.edu.tr.
Erciyes University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextIn sporadic acromegaly, overall AIP(mut) prevalence is reported as 3, 4.1 and 16 % in studies carried out across Europe. However, it is not known whether the prevalence shows any changes across different ethnicities. The aim of the study was to identify prevalence of AIP(mut) in a series of Turkish acromegalic patients. PATIENTS AND

methodsDirect sequencing of AIP gene was performed in 92 sporadic acromegalic patients.

resultsOne patient was found to have a new mutation in exon 6: g67.258,286 (G/A) heterozygote; (GGC/GAC; gly/asp). Apart from this new mutation, previously defined synonymous mutations in AIP gene were detected in seven patients (Exon 4; rs2276020; (GAC/GAT; asp/asp) and six patients were found to have five different intronic mutations in AIP gene which were not previously defined. The patient with pathogenic AIP(mut) presented at a young age and had an aggressive and treatment resistant tumour. The prevalence of AIP(mut) in Turkish patients was found to be 1 % in sporadic acromegaly in the present study. In addition, one synonymous mutation which was previously defined and six new intronic mutations have been described in Turkish acromegalic patients. All acromegalic patients with synonymous AIP(mut) presented with macroadenoma and majority of them had invasive tumour.

conclusionThe prevalence of AIP(mut) in Turkish patients was found to be 1 % in sporadic acromegaly in the present study. This ratio increases when younger age groups are taken into account 6 % among patients <30 years of age at the time of diagnosis of acromegaly. The clinical features of acromegaly, such as having large and invasive tumours, may be affected by the presence of synonymous AIP(mut).

Indexed as

AcromegalyAdultFemaleHeterozygoteHumansIntracellular Signaling Peptides and ProteinsMaleMiddle AgedMutationPrevalenceTurkeyaryl hydrocarbon receptor-interacting proteinIntracellular Signaling Peptides and ProteinsAcromegalyAIP mutationSynonymous mutationTurkey

Identifiers

PMID26021842
OpenAlexW352282082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.